1. Introduction {#sec1}
===============

It is estimated that up to 30% of patients with cancer will develop brain involvement \[[@B1], [@B2]\]. Breast cancer, nonsmall cell lung cancer, and melanoma have shown a predilection for brain metastasis \[[@B3], [@B4]\]. Brain metastases are 10 times more common than primary brain tumors, resulting mostly from carcinomas \[[@B1]--[@B4]\]. The incidence is much lower in the pediatric population with estimates of 1.5--2.5% \[[@B3]\].

Accounting for 0.8% of all cancers, musculoskeletal bone and soft tissue sarcomas make up a small portion of patients with brain metastases \[[@B4]\]. It is estimated that 3% of all brain metastases are sarcomas and 1--8% of all sarcoma patients may develop brain involvement \[[@B1], [@B2]\]. However, there is mounting evidence that the incidence is increasing due to new chemo- and radiotherapeutic treatments that prolong survival through systemic disease control but without effective intracranial control \[[@B2], [@B5]\]. Unlike many other brain metastases, sarcomas tend to be highly radio- and chemoresistant with surgical resection as the basis for management \[[@B1]\]. Mechanisms of sarcoma spread to the brain are twofold: hematogenous dissemination into brain parenchyma and contiguous extension of metastases in bones of the skull into intracranial structures \[[@B6]\].

The purpose of this review is to present the current literature on brain metastasis (BM) from bone and soft tissue cancers, with an emphasis on musculoskeletal sarcomas and those most commonly metastasizing to the brain. We describe the incidence, diagnostic strategies, treatment paradigms, and prognostic outcomes as well as relevant background information.

2. Methods {#sec2}
==========

A search of the published literature was conducted for patients with brain metastasis from musculoskeletal sarcomas. The national library of medicine search engine, PubMed, was utilized for the literature search. For each of the sarcomas, the search terms "brain" and "intracranial" were combined with the tumor\'s name: "osteosarcoma," "Ewing\'s sarcoma," "chondrosarcoma," "chordoma," "malignant fibrous tumor," "malignant fibrous histiocytoma," "fibrosarcoma," "liposarcoma," "alveolar soft part sarcoma," "rhabdomyosarcoma," "malignant peripheral nerve sheath tumor," "MPNST," or "angiosarcoma." Relevant articles describing case reports or clinical studies were selected, and the reference lists from these articles were also inspected for other relevant articles. Each of the resultant articles were examined closely and reported in this review. Cases in which there was contiguous extension of a primary tumor into intracranial structures (i.e., a skull tumor) as opposed to frank metastasis from a distant site were excluded. Only publications in English, peer-reviewed journals were included.

3. Results {#sec3}
==========

3.1. Malignant Bone Tumors {#sec3.1}
--------------------------

The primary malignant bone tumors discussed are the most commonly reported to metastasize to the brain: osteosarcoma (osteogenic sarcoma), Ewing\'s sarcoma, chondrosarcoma, chordoma, and fibroblastic/fibrohistiocytic tumors.

### 3.1.1. Osteosarcoma (Osteogenic Sarcoma) {#sec3.1.1}

After plasmacytoma (33%), osteosarcoma (20%) is the most frequently occurring primary malignant bone tumor \[[@B7]\], characterized by osteoid producing atypical cells \[[@B8]\]. In children, osteosarcoma is the most common bone cancer \[[@B9]\]. Dissemination is typically via the bloodstream, primarily targeting lungs and other bones \[[@B10]\]. BM is rare, with a reported incidence of 1.8--5.6% \[[@B3]\], and associated with prior pulmonary metastasis \[[@B11]\], with the hypothesis of lung tumor emboli invading the brain. Nonetheless, there are several reports of BM without active lung involvement. An increased risk of BM with metastatic disease at presentation or with recurrence at 1 year has been reported \[[@B3]\]. As in other BM, those from osteosarcoma typically locate through the anterior circulation to the gray-white matter junction \[[@B12]\]. Multimodality treatment is often involved, though no consensus on treatment exists.

[Table 1](#tab1){ref-type="table"} summarizes published cases of osteosarcoma patients with BM \[[@B2]--[@B5], [@B9], [@B13]--[@B28]\]. A total of 55 patients are presented, with an average age of 18 years and a male: female ratio of 3 : 2. Location of the primary was variable, with majority localized to the femur. BM management almost always involved surgical resection (SR). This was followed by whole brain radiation therapy (WBRT) and/or chemotherapy in select cases. Mean interval to BM from initial diagnosis (IB) was approximately 18.9 ± 21.1 months (range 0--110) from diagnosis of the primary, and overall mean survival (OS) was approximately 18.4 ± 30.4 months following its detection. A possible predilection for synchronous metastasis has also been highlighted \[[@B13], [@B14]\]. Location of metastatic lesions varied throughout the cerebrum with the frontal lobe being the most common single lesion.

Yonemoto et al. \[[@B18]\] recommended performing brain imaging periodically in patients with known active pulmonary metastasis. This was echoed by Marina et al. \[[@B19]\] for those with metastatic disease at diagnosis or in whom recurrence develops within 12 months, though whether routine imaging will improve outcomes is debatable \[[@B3]\]. Though surgery was previously advocated only in patients with solitary BM without systemic disease, more recently concurrent systemic disease has been suggested not to be a contraindication for SR \[[@B15], [@B16]\]. Paulino et al. \[[@B17]\] reported RT to slow neurological deterioration in their cohort of pediatric patients. Unlike the majority of the authors, Flannery and colleagues \[[@B15]\] utilized Gamma Knife Stereotactic Radiosurgery (GKSRS) in their management and noted the modality to be a viable alternative to surgery in select cases.

As a commonly diagnosed musculoskeletal cancer in children and young adults, osteosarcoma, when metastatic, mainly spreads to the lungs and other bones and rarely to the brain. As such, it is difficult to form consensus guidelines on treatment once BM occurs. As many of these lesions are solitary, surgical excision has been the standard of care, with chemotherapy and RT for palliative measures.

### 3.1.2. Ewing\'s Sarcoma {#sec3.1.2}

Ewing\'s sarcoma is commonly seen in young adults and has a slight male predominance \[[@B29]--[@B31]\]. Up to 80% of patients have subclinical metastases at time of presentation \[[@B29]\]. It comprises about 10% of primary malignant bone tumors and, like osteosarcoma, the lungs and distant skeletal tissues are common metastatic sites \[[@B31]\]. CNS metastases have been reported in 32--56% of cases, frequently a result of direct extension of bony metastases in close proximity, with BM making up \<1.8% of cases \[[@B32]\]. Extremity tumors generally have better prognosis than axial skeleton primaries, which are arduous to completely excise \[[@B31]--[@B33]\]. BM usually appears as part of systemic disease, with more than 85% having lung involvement \[[@B33]\].

Approximately 40 cases of ESBM have been described in the literature ([Table 2](#tab2){ref-type="table"}) \[[@B2], [@B4], [@B9], [@B15]--[@B17], [@B22], [@B26], [@B30], [@B32], [@B34]--[@B39]\]. Average age of patients is approximately 20.9 years with \>65% males. The majority of BM is localized to the parietal lobe (16) 41%, 12 (31%) to frontal lobe, and 5 (13%) to temporoccipital lobes. IB was 23.2 ± 27.1 months (range: 0--115), with OS of 7.1 ± 7.7 months (range: 0--24) following detection. A combination of treatments was utilized in 17 patients (44%), with 22 given chemotherapy (56%). Reportedly, concomitant use of chemotherapy has increased long-term survival rates to 50--70% \[[@B29]\]. Specific treatments for BM included SR (25%), WBRT (70%), GKSRS (17.5%), and conservative management (17%). Primaries originated most commonly from lower extremities and were generally treated with RT and SR, with SR mostly utilized for axial skeleton tumors.

Overall, the appearance of BM signifies a poor prognostic outcome in patients with ES. The current increased frequency of CNS metastases has been linked to prolonged survival and alteration of host response following chemotherapy \[[@B26]\]. Moreover, recent therapies for metastatic ES have not substantially improved outcomes since the initiation of multidrug chemotherapy \[[@B29], [@B34]\]. As one of the more common sarcomas metastasizing to the brain, it is hoped that future research may herald improved treatments.

### 3.1.3. Chondrosarcoma {#sec3.1.3}

Chondrosarcoma is a malignancy of mesenchyme that is a common primary bone tumor subsequent to osteosarcoma in frequency \[[@B40]\]. It has been classified based on histological appearance into slow growing, benign grade I to malignant grade III \[[@B40], [@B41]\]. Distant metastases account for 10% of grade II and 71% of grade III \[[@B41]\], commonly occurring to lungs, other bones, and liver, resulting in a mere 5-year survival of 18% \[[@B40]\]. Primary intracranial chondrosarcoma constitutes only 0.16% of all intracranial tumors. BM is exceedingly rare with only few documented cases \[[@B42]\]. Due to their sporadic nature, treatment options are extrapolated to other sarcomatous metastases.

[Table 3](#tab3){ref-type="table"} summarizes 12 previous chondrosarcoma patients with BM and shows an average age of 43.4 years, with 6 males and 6 females (50%) \[[@B15], [@B40]--[@B49]\]. There were 2 children (age 18 and younger). Locations of the primary tumor were variable with 6 cases in the extremities (50%) and most often treated with SR or amputation. BM was variable in location and occurred with an IB of 7.9 ± 10.6 years (range: 0.5--34). OS was 16.9 ± 16.7 months (range: 2--44) after BM. Most common treatments were SR in 4 cases (33.3%) and GKSRS in 3 cases (25%). Out of 6 cases in which cause of death was specified, 3 expired due to progressive neurologic disease and 3 expired from systemic disease.

Treatment with chemo- and radiotherapy has resulted in poor results, postulated due to the resistant extracellular matrix, low mitotic index, and sparse vascularization of cells \[[@B40], [@B43]\]. As such, SR was utilized in most of the documented cases, though outcomes were dismal ([Table 3](#tab3){ref-type="table"}). Flannery et al. \[[@B15]\] reported their experience with GKSRS in 21 patients with 60 sarcomatous BM, 2 from chondrosarcoma. Overall, the treatment resulted in a local tumor control rate of 88% with a median survival of 16 months following BM diagnosis. Tsutsumi et al. \[[@B41]\] also reported their experience with GKSRS in a 60-year-old male with chondrosarcoma BM that resulted in adequate control for over 10 months. Thus, GKSRS can be an effective option for these BM, especially small lesions.

Though chondrosarcoma accounts for 40% of primary bone cancers in adults \[[@B43]\], it rarely metastasizes to the brain but it can occur many years down the line. Once BM is diagnosed, it is usually treated with excisional surgery because of resistance to chemotherapy and radiotherapy \[[@B41]\]. More recently, GKSRS has shown promise to be an effective modality with long-term survival and improvement in quality of life.

### 3.1.4. Chordoma {#sec3.1.4}

Chordomas are rare, malignant tumors, which arise from the embryonic notochord \[[@B50]--[@B52]\]. Their indolent and progressive course often correlates with a poor prognosis in which they silently expand for years without any clinical symptoms \[[@B50], [@B51]\]. They are quite uncommon, representing 4% of all malignant tumors of bone \[[@B52]\] and less than 1% of spine tumors \[[@B53]\]. Only about 70 metastasizing cases have been reported, characterizing chordomas as more locally invasive and less susceptible to distant metastasis \[[@B52]\]. There is a male predominance overall, though sacrococcygeal chordomas are more frequent in females \[[@B54]\]. No age preference is apparent, with children as young as 2 and adults in their 70 s afflicted \[[@B51]\]. The pediatric population, however, has been reported to harbor an aggressive form \[[@B53]\]. While the most common site of presentation is the caudal and cranial poles of the spine \[[@B55]\], chordomas are generally characterized into one of three principal clinicoanatomical categories: cranial, vertebral, and sacrococcygeal \[[@B50]\]. According to Hall and Clark, 50% of patients have sacrum or coccyx involvement followed by 33% with clival involvement \[[@B52]\].

Inherently, chordomas destroy and replace bone in which they develop \[[@B56]\]. Until recently, it was thought that it spreads via direct extension, suggesting frank metastasis seldom occurs \[[@B55]\]. However, latest literature explores many cases of metastasis---especially in those presenting at sacrococcygeal sites. It is estimated 25--43% of sacrococcygeal chordomas will present with subsequent metastasis \[[@B52]\], most often to lymph nodes, liver, and lungs \[[@B55]\]. Metastasis presenting in the brain remains rare \[[@B52]\], and complete resection of the primary is vital for prevention and overall patient survival \[[@B54]\]. [Table 3](#tab3){ref-type="table"} outlines characteristics from published case reports on BM from chordoma \[[@B50], [@B52]--[@B57]\]. Though SR and RT were initiated, most patients died shortly after brain involvement.

Metastasis from chordomas depends on many factors such as histology, mitotic activity, and treatment regimens \[[@B54]\]. Due to their rarity, optimal treatment remains with disappointing results. Surgical excision, while still the recommended treatment course for cure, is frequently not possible \[[@B56]\] though it does provide a palliative measure to reduce tumor load for subsequent chemotherapy \[[@B53]\]. The challenge continues as chordomas are also relatively radio- and chemoresistant \[[@B52], [@B56]\]. Further research is vital in order to discover satisfactory alternatives for appropriate therapy.

### 3.1.5. Fibroblastic and Fibrohistiocytic Tumors {#sec3.1.5}

Previously designated under "malignant fibrous tumors," these are rare malignancies characterized by pleomorphic, high-grade tumor cells with histiocytic, fibroblastic, and myofibroblastic features \[[@B58]--[@B60]\]. "Malignant fibrous histiocytoma (MFH)" has been renamed "undifferentiated pleomorphic sarcoma (UPS)" in the most recent WHO Classification of tumors of soft tissues and bone \[[@B59]\]. They rarely occur in children \[[@B60]\] and the predominant affected population is typically adult males \[[@B61]\]. Most common primary tumor sites are the extremities and retroperitoneum \[[@B58]--[@B61]\]. There is an exceedingly high reoccurrence rate, with some studies reporting as high as 44% \[[@B58]\]. The prognosis is generally poor with a 42% risk of distant metastasis \[[@B58], [@B62], [@B63]\]. Sites of metastasis include lungs, liver, bone, and, very rarely, brain \[[@B58], [@B60], [@B64], [@B65]\].

Although these tumors can originate from either bone or soft tissue, defining the source is difficult \[[@B66]\]. Successful SR of the primary site with clear margins can be difficult; thus, local recurrence and metastasis are frequent. Both soft tissue and bone forms have the propensity for BM as the incidence at autopsy has been reported at 1.5% \[[@B65], [@B67]\]. Patients experiencing BM remain asymptomatic prior to events such as intracranial hemorrhage (ICH), which has been shown to occur \[[@B62], [@B68], [@B69]\]. Prognosis after detection of BM varies significantly and can be affected by the primary site, with soft tissue locations being more susceptible to multiple metastases \[[@B70]\].

As with other sarcomas, pulmonary metastasis is most common, with its detection increasing the risk of future BM \[[@B67], [@B69]\]. Thus, both the primary site and the site(s) of metastasis are essential in accurate prognosis of patients. As shown in [Table 4](#tab4){ref-type="table"}, the majority were MFH/UPS (17, 54.8%), with the rest being fibrosarcomas (10, 32.3%) and dermatofibrosarcomas (3, 9.7%) \[[@B2], [@B5], [@B33], [@B39], [@B43], [@B58]--[@B74]\]. Multimodality treatment was utilized in many cases, including SR, chemotherapy, WBRT, and STRS. The IB was 33.2 ± 41.0 months ranging from 0 to 312 months. OS also was variable with a mean of 10.6 ± 17.1 months following BM, and a male predilection was observed (55.6%).

Periodic imaging of the brain, the primary site, and the metastatic sites has been suggested to prolong life expectancy, though it remains controversial \[[@B65]\]. In addition, as these metastases tend to bleed, many patients often become symptomatic only after ICH, further reiterating the significance of routine screening in susceptible patients \[[@B62], [@B65], [@B68]\]. Similarly, the therapeutic range of chemotherapeutic agents must be monitored in an organ-specific manner for maximal efficacy \[[@B64]\]. Although cases of BM are uncommon, vigilance is warranted, particularly through frequent neurological examination in all patients and routine imaging in select cases \[[@B69]\].

3.2. Malignant Soft Tissue Tumors {#sec3.2}
---------------------------------

The primary malignant soft tissue tumors (STS) discussed are also the most likely to metastasize to the brain: liposarcoma, rhabdomyosarcoma, malignant peripheral nerve sheath tumor, angiosarcoma, and alveolar soft part sarcoma.

### 3.2.1. Liposarcoma {#sec3.2.1}

Liposarcomas comprise about 10--20% of all STS \[[@B75]--[@B77]\]. While uncommon in children, liposarcoma is currently the second most frequent soft-tissue malignancy in adults \[[@B76]\]. Middle-aged and older adults are most susceptible \[[@B75]\], presenting most frequently deep within soft tissues of proximal extremities and retroperitoneum as large, bulky masses \[[@B75], [@B77], [@B78]\]. The incidence of BM after liposarcoma diagnosis is exceedingly rare and is most often preceded by pulmonary metastasis \[[@B76], [@B78]\].

Espat et al. \[[@B79]\] analyzed the cohort of 3829 patients from the Memorial Sloan Kettering Cancer Center between 1982 and 1999 who presented with STS. Forty patients (\>1%) presented or developed STS BM, 5 (12.5%) of which were liposarcoma patients---the second leading tumor causing STSBM in the cohort. Previous liposarcoma patients with BM are summarized in [Table 5](#tab5){ref-type="table"} \[[@B2], [@B75]--[@B78], [@B80]--[@B83]\]. Average patient age is 52.3 years. Parenchymal involvement included the temporoparietal region (44%), frontal region (22%), parafalcine (11%), and skull base (11%). The majority originated in the thigh and most patients received SR with or without chemotherapy and/or RT. The same is appreciated for the BM; SR was offered to most, combined with another modality for a few. IB was 127.5 ± 124.0 months and ranged from 0 to 313 months. Survival following BM is unfavorable even after SR, and the use of chemo- and radiotherapy is questionable at best.

As the lifespan of patients diagnosed with liposarcoma extends, the natural history of the disease leads to CNS metastases, which occurs in a large part after 10 years following original diagnosis \[[@B2], [@B77], [@B80]\]. Histologically, the degree of differentiation also contributes to the likelihood of metastasis \[[@B81]\]. Kumar and Teasdale \[[@B82]\] noted that the myxoid type liposarcomas have the lowest rates of BM while pleomorphic types have the highest \[[@B76], [@B83]\]. Additionally, the origin of the liposarcoma dictates the extent of relapse \[[@B75], [@B79]\]. Regardless of the available treatments, BM from liposarcomas is very unusual and should only be considered after relevant neurological findings \[[@B2], [@B75]\].

### 3.2.2. Rhabdomyosarcoma {#sec3.2.2}

Rhabdomyosarcoma (RMS) is a malignancy of striated muscle and one of the common STS in those under 20 years \[[@B84]\]. It usually arises from the head and neck, genitourinary system, and the extremities \[[@B85]\]. BM from RMS is exceedingly uncommon and is accompanied with neurologic symptoms in a minority of patients \[[@B85], [@B86]\]. In his 1988 review, Lewis reported the detection of pulmonary metastases from RMS may indicate an increased risk of future BM \[[@B67]\]. Common metastatic sites are lungs, pleura, pancreas, and bones and occurs via blood or lymph flow \[[@B84], [@B90]\].

Vezeridis et al. \[[@B87]\] reviewed 242 patients with recurrent STS between 1960 and 1978; 68 (28.1%) were metastatic RMS. In a Japanese study with 480 sarcoma patients \[[@B88]\], 2 of the 13 with metastatic RMS had BM (15.4%). Parasuraman et al. \[[@B36]\] documented patients treated at St. Jude Children\'s Hospital from 1962 to 1998 with BM from RMS. Out of 419 patients, 10 developed BM (2.4%). Median interval between primary tumor and diagnosis of BM was 1 year. The authors also showed that combined RT and chemotherapy prolong survival and improve prognosis, with an estimated 1-year survival of 30%. Another study reported RT alone was inadequate while intensive chemotherapy and high dose RT to the primary site had a survival of 74% with a local control rate of 89% \[[@B89]\].

Like other sarcomas, multimodality treatment is instigated for those with BM from RMS \[[@B84]\]. Gasparini et al. \[[@B90]\] tracked two series of children with head and neck RMS and intracranial involvement. They found that CNS prophylactic chemotherapy and higher doses of RT resulted in a better ability to achieve persistent local tumor control. As shown in [Table 5](#tab5){ref-type="table"}, previously reported cases of RMS with BM \[[@B2], [@B3], [@B15], [@B17], [@B33], [@B36], [@B69], [@B84]--[@B86], [@B88], [@B91], [@B92]\] have an average age of 12.0 years, with majority being males (21, 56.8%). Most were children (89.2%) including 5 neonates. Thirteen tumors originated from the extremities (35.1%) and treatment of the primary was multimodal. BM were in variable locations including 7 parietal (18.9%), 7 frontal (18.9%), and 5 cerebellar (13.5%). IB is 1.7 ± 2.3 years (range: 0--12.2) and OS was 15.6 ± 16.0 months (range: 0--207). Treatments included WBRT in 20 cases (54.1%), chemotherapy in 18 (48.6%), and SR or GKSRS in 8 (21.6%). Cause of death was neurologic deterioration in 12 (32.4%) and systemic disease in 10 (27.0%), with the rest alive at last followup.

RMS is a common STS affecting young patients, and it has been known to metastasize to different organs and tissues. Patients with a history of metastasis have a significant risk of future BM \[[@B3]\]. Surgical treatment for select patients can result in long-term survival \[[@B87], [@B88]\], and increasing doses and volume of RT have been shown to prolong survival \[[@B90]\]. Overall, a combined modality approach is advocated.

### 3.2.3. Malignant Peripheral Nerve Sheath Tumors {#sec3.2.3}

A number of entities are synonymous with malignant peripheral nerve sheath tumors (MPNST) including neurofibrosarcoma, neurogenic sarcoma, and malignant schwannoma \[[@B93]\]. MPNST usually arise from nerves of extremities and trunk or from preexisting neurofibromas and account for less than 10% of all STS \[[@B94], [@B95]\]. Uncommon in the general population with an incidence of 0.001%, it is much more common in those with neurofibromatosis type 1 (NF-1) \[[@B94]\]. Surgery is the primary treatment of MPNST with the aim of radical en bloc SR \[[@B94], [@B96]\], followed by RT for local control whether clear surgical margins are achieved or not \[[@B94], [@B97], [@B98]\]. Due to its infrequency, outcomes are difficult to determine, though reportedly poorer than other sarcomas \[[@B93], [@B99]\]. The incidence of BM is exceptionally rare with only 21 documented cases ([Table 6](#tab6){ref-type="table"}) \[[@B15], [@B93]--[@B95], [@B100]--[@B117]\].

According to [Table 6](#tab6){ref-type="table"}, MPNST patients with BM have an average age of 36.6 years, with 2/3 males and 4 (19.0%) children. Location of the primary neoplasm varies and its treatment almost always involves surgical resection (SR). The frontal lobe was the most common location for BM (28.6%) and the infratentorial region was involved in 6 cases (28.6%). IB occurred at 32.4 ± 54.5 months (range: 0--180) and OS was 9.9 ± 15.2 months (range: 1--16) following BM. Additionally, at mean follow-up of 42.6 months, 2 patients (10.5%) remained alive. Seven (33.3%) had a history of NF-1. The majority of cases expired due to widely metastatic disease.

Aggressive SR followed by WBRT is the basis of treatment for BM. However, because of the limited pool of patients, there are cases surviving for many months without treatment and others dying over a short period after aggressive intervention \[[@B94], [@B95], [@B100]\]. Tilgner et al. \[[@B93]\] reported on a patient with 2 BM treated by WBRT and SR of only one of the lesions. Interestingly, there was local control of both lesions at 14 months, highlighting the importance of WBRT for MPNST BM. The importance of RT should not be underestimated, as one reported case with cerebellar metastasis was treated with en bloc SR without RT only to have local recurrence 4 months later \[[@B95]\]. Another report presented GKRS as a viable option for multiple BM with excellent initial and long-term response \[[@B101]\]. Park et al. \[[@B102]\] noted the tumor\'s tendency to bleed on presentation and our review builds on this as 5 (23.8%) of all reviewed cases had ICH on presentation ([Table 6](#tab6){ref-type="table"}). Cerebrospinal fluid dissemination is hypothesized as the likely route \[[@B103]\], though hematogenous metastasis, cannot be excluded.

MPNST is a very aggressive cancer associated with high recurrence and metastatic potential. Prognosis is generally poor and worse with metastasis \[[@B103], [@B105], [@B104]\]. It does have the potential for BM, though reported mainly in case reports. A greater potential for BM may exist from spinal tumors ([Table 6](#tab6){ref-type="table"}). Treatment should involve aggressive SR combined with RT. Overall, the appearance of BM signifies an impending poor outcome in patients with MPNST. More cases and studies should be reported to help establish a suitable therapeutic approach.

### 3.2.4. Angiosarcoma {#sec3.2.4}

Angiosarcoma is an exceedingly rare malignancy, which arises from endothelial cells of the vasculature. The least common among vascular tumors, angiosarcoma has a prevalence of \<1% of all sarcomas \[[@B118], [@B119]\]. Certain described risk factors include vinyl chloride exposure, chronic lymphedema, and arsenic exposure \[[@B120]\]. They occur mainly in the head, face, liver, skin, and other soft tissues. Most skin and soft tissue angiosarcomas are treated with SR along with adjuvant chemotherapy or RT \[[@B119]\]. BM is unusual, with only a few reported cases ([Table 6](#tab6){ref-type="table"}).

Current understanding of the metastatic behavior of angiosarcomas is limited. Of reported cases with BM, the often involved primary site is the heart \[[@B122]\]. Though, in a retrospective analysis of primary neoplasms of the heart only 2% were angiosarcomas \[[@B120]\]. Review of literature also showed 6 cases of metastatic splenic angiosarcoma, 2 with BM. [Table 6](#tab6){ref-type="table"} \[[@B32], [@B118]--[@B131]\] shows an average age corresponding to 42.3 years with 70% males. Origin was overrepresented by thoracic or abdominal angiosarcomas (66.6%). Treatment involved SR 93.3% of the time (14/15) and localized RT in only 2/15 cases (13.3%). IB was approximately 16.4 ± 21.7 (range: 0--72) and OS was 4.8 ± 7.3 months, following conservative palliative treatment in 7 (46.6%) and SR in another 7 (46.6%). Metastases were reported mostly in the parietal (30.7%) or frontal lobe (23%). Most expired secondary to systemic complications.

Overall, the prognosis of angiosarcoma is grim. Typical 5-year survival is 12%, with metastases and reoccurrence typically occurring within the first 2 years \[[@B119]\]. Prognosis varies highly with the primary site \[[@B123]\], and surgical resection is often difficult because of hefty tumor size at presentation \[[@B120]\]. Once angiosarcoma has metastasized, especially to the brain, mean survival is decreased to 2--6 months, signifying a bleak outcome.

### 3.2.5. Alveolar Soft Part Sarcoma {#sec3.2.5}

Alveolar soft part sarcomas (ASPS) account for a small percentage of STS at roughly 1% \[[@B88], [@B89]\]. In contrast to bone-part tumors, ASPS is a soft-part tumor that presents mainly in muscle and deep soft tissue of the thigh or leg \[[@B132]--[@B136]\]. A malignancy found in younger patients, those diagnosed are mostly below the age of 40 years \[[@B132], [@B133], [@B136], [@B137]\]. While it metastasizes to lung and bone, unlike other sarcomas, it has a predisposition towards BM with estimates of 15 to 30% in those with stage IV disease \[[@B1], [@B134]\]. On the other hand, ASPS patients have been reported to have greater oncological control with better relapse-free survival \[[@B1]\]; even though 25% of patients have metastasis at presentation, overall survival is comparatively high at 10--12 years \[[@B138], [@B139]\].

Portera et al. \[[@B137]\] studied a large cohort of 74 patients with ASPS. The majority (65%) presented with Stage IV disease and BM (19%) was only present in those with other metastases, particularly lung. Eight (88.9%) of the 9 patients with BM developed neurological symptoms, and imaging performed in those without such symptoms did not reveal occult BM. Resistance to conventional chemotherapy was noted and overall survival was 40 months. Daigeler et al. \[[@B132]\] described similar result in their small series and recommended SR followed by RT for both the primary and resectable metastases and found tumor size at presentation to not influence long-term results.

The literature is abundant with reports of BM from ASPS. [Table 7](#tab7){ref-type="table"} presents a summary of cases from published series \[[@B2], [@B4], [@B5], [@B15], [@B39], [@B132], [@B137], [@B141], [@B142]\]. The IB ranged from 1 to 156 months, roughly averaging 29 months. Patient\'s age was approximately 30 years, without a remarkable predilection to any one of the sexes. OS ranged significantly (1--36 years), with a mean between 3 and 4 years \[[@B132]\]. Five-year survival reportedly ranges between 59 and 67% \[[@B136]\]. Long-term survivors have been known to exhibit spontaneous regression phenomenon, in which there is partial or complete disappearance of the malignancy in absence of traditional treatment \[[@B133]\].

Neurosurgical resection can be favorable and may increase long-term survival \[[@B1], [@B135], [@B136], [@B134]\]. A surgical advantage may exist with ASPS when compared to other sarcomas. There is little evidence to support routine brain imaging without metastatic disease at other sites. Chemotherapy has not been found to be helpful, as there is frequently lack of response. Even though ASPS has a larger predisposition for BM, patients with ASPS BM generally have a better prognosis than other bone and soft tissue malignancies \[[@B1]\].

### 3.2.6. Other Soft Tissue Sarcomas {#sec3.2.6}

Malignant histiocytomas (undifferentiated pleomorphic sarcomas) and fibrosarcomas originating from the soft tissues are covered under the*fibroblastic and fibrohistiocytic* tumors section. Also, [Table 4](#tab4){ref-type="table"} includes previous such cases originating from soft tissues with BM. Brain metastases from leiomyosarcomas are frequently reported; however, they rarely originate from musculoskeletal structures. For instance, Salvati et al. \[[@B2]\] have reported 7 cases of brain metastasis from leiomyosarcoma. Most of these cases had their primary site as the uterus, with others reporting ovarian and gastrointestinal origins \[[@B3]\]. Others have reported BM from gastrointestinal origins such as GIST \[[@B143]\].

4. Discussion {#sec4}
=============

Previous landmark studies on the treatment of brain metastases have shown efficacy in surgical resection and postoperative WBRT \[[@B144], [@B145]\], as well as stereotactic radiosurgery \[[@B146]\]. Most such studies have focused on common sources of BM such as lung, breast, and genitourinary cancers. Here, via a thorough literature search, we presented an up-to-date and comprehensive review of the current literature regarding BM from bone and STS. The literature on this topic is limited to case reports and case series. Consequently, variable results are reported with regard to prevalence, management, and outcomes. A few points are noteworthy, however.

Generally, BM from these cancers is very infrequent, most commonly occurring in Ewing\'s sarcoma, fibroblastic/fibrohistiocytic tumors, and osteosarcoma. Pediatric patients are more likely to have RMS. Though ASPS commonly metastasizes to the brain, it is a much rare cancer and thus accounts for a lesser proportion. Many of the larger studies suggest a slight preponderance in males (52--60%) \[[@B2], [@B5], [@B9], [@B39], [@B147]\]. It is a disease of younger patients with an average age range between 12 and 52 years and a mean of 32.5. The most important factor in developing BM in many of these cancers is a history of pulmonary metastasis. Most common locations for metastasis follow the anterior circulation, hence, the cerebral hemispheres. Additionally, they tend to be single lesions (\>60%), rather than multiple \[[@B2]\]. The point at which BM occurs in these patients is unpredictable, with many found at presentation and others developing many months or even years later. An estimate in the range of 20--30 months is suggested by the literature \[[@B2], [@B5], [@B9], [@B39], [@B147]\], with most being detected before 24 months (osteosarcoma, Ewing sarcoma, chordoma, angiosarcoma, and rhabdomyosarcoma), some at 24--36 months (fibroblastic/fibrohistiocytic tumors, malignant peripheral nerve sheath tumors, and alveolar soft part sarcoma) and a few after \>36 months (chondrosarcoma, liposarcoma). Liposarcoma and chondrosarcoma have repeatedly been reported to develop BM many years following initial diagnosis.

Comprehensive neurological evaluation and imaging should be performed on development of suspicious neurological signs or symptoms. Clinical presentation of BM is characterized by rapid onset of neurological symptoms, such as paresthesias, visual field defects, and headache. Generally, routine neuroimaging studies without these indications are not warranted because of the rarity of BM and because they almost always result in signs and symptoms if they are present though it has been suggested to screen patients with osteosarcoma and MFT with extensive disease, especially if there is a short disease free interval \[[@B18], [@B19], [@B65]\].

The extent of systemic disease and Karnofsky Performance Scale (KPS), as well as sarcoma histotype are important factors in determining patient outcomes. The presurgical KPS gives an overall clinical picture, and a score above 60--70 has been cited as a good prognostic indicator associated with higher median survival \[[@B2], [@B5], [@B9], [@B39], [@B147]\]. In addition, repeatedly throughout the literature the presence and degree of extracranial involvement have been cited as a very important consideration in management of decision making and predictor of survival. As many of these cancers tend to be radio- and chemoresistant \[[@B1], [@B2]\], their management becomes challenging. Surgical resection of their BM can improve neurological function and is a safe, feasible option in select patients with a favorable KPS and controlled systemic disease. This intervention should be also considered for solitary brain lesions with sequelae and/or mass effect. Enhancements in surgical methods, anatomical navigation tools, brain mapping techniques, and awake neurosurgery have made it possible to excise multiple lesions in previously considered inoperable locations \[[@B1], [@B2]\].

While SR has been suggested to lead to improved outcomes \[[@B1], [@B2], [@B5], [@B9], [@B39], [@B147]\], it is not an option for many patients. When the number of metastatic foci is beyond a certain point (2-3), STRS should be considered and can provide similar or even better results \[[@B15]\]. This modality should be considered in those with less than 6 lesions, each \< 3--3.5 cm in diameter \[[@B15]\]. Palliative treatment with WBRT and chemotherapy should be provided to those with many BMs and concurrent systemic disease, keeping in mind that an aggressive approach with multimodality treatment with or without SR can be judiciously given to certain patients as stated above. More recent studies have highlighted the potential of new chemotherapeutic and radiotherapeutic adjuvants \[[@B148], [@B149]\]. Overall mean survival is estimated at 7--16 months, with the majority surviving \<12 months (Ewing\'s sarcoma, liposarcoma, fibroblastic/fibrohistiocytic tumors, malignant peripheral nerve sheath tumors, angiosarcoma, and chordomas) and a minority \>12 months (osteosarcoma, chondrosarcoma, rhabdomyosarcoma, and alveolar soft part sarcoma). Bone and soft tissue BM in children is more atypical and is even more problematic to make meaningful conclusions on management and outcomes.

5. Conclusion {#sec5}
=============

Brain metastasis in bone and soft tissue cancers usually occurs late in the malignancy. As most of the data in the literature is from case reports and case series utilizing heterogeneous treatments, it is difficult to discern the best therapeutic strategy. Prolonged survival and an adequate quality of life are achievable in a small, select population of patients. While such a survival advantage may exist for those given an aggressive treatment course involving surgical resection, it should be reserved for those with a favorable preoperative performance status and minimal systemic disease. Future large prospective studies can help give more insight on this uncommon, yet growing group of brain metastases. Overall, the occurrence of BM in patients with bone and soft tissue cancers is a poor prognostic sign that suggests late stage disease.
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###### 

Comparison of published reports detailing characteristics of patients with brain metastases from primary osteosarcoma.

  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Case author                                   Age, sex        Primary site                         Primary treatment    IB Mo    Metastatic site                                     Metastatic treatment        OS Mo          Special aspects
  --------------------------------------------- --------------- ------------------------------------ -------------------- -------- --------------------------------------------------- --------------------------- -------------- ---------------------------------------------------------------
  Rabah et al., 2013 \[[@B13]\]                 10 F            Right humerus                        (None)               0^a^     Right frontal lobe                                  Chemo, WBRT                 14             Cerebral metastasis on presentation

                                                                                                                                                                                                                                  

  Onodera et al., 2012 \[[@B14]\]               14 F            Left femur                           Surgery, chemo       12       Right parietal lobe                                 SR                          NR             No active pulmonary metastasis

                                                                                                                                                                                                                                  

  Chou et al., 2011 \[[@B4]\]                   *N* = 5 \       NR                                   NR                   NR       Single cerebrum (3); multiple (2)                   SR + RT                     D               
                                                15--58, M (4)                                                                                                                                                                     

                                                                                                                                                                                                                                  

  Flannery et al., 2010 \[[@B15]\]              *N* = 3 \       Pelvis, femur, humerus               Chemo                NR       1 single, 2 multiple                                GKSRS                       36--84         Gamma knife radiosurgery as therapy
                                                17--37, M (3)                                                                                                                                                                     

                                                                                                                                                                                                                                  

  Salvati et al., 2010, 1998 \[[@B2], [@B9]\]   *N* = 10 \      Femur, tibia                         NR                   0--110   Frontal (5), multiple (3), parietal, temporal       SR + WBRT                   NR              
                                                11--60, M (5)                                                                                                                                                                     

                                                                                                                                                                                                                                  

  Niazi et al., 2009 \[[@B20]\]                 16 M            Right femur                          (None)               0^a^     Left cerebellum                                     SR                          6 days         Posterior fossa hemorrhage on presentation

                                                                                                                                                                                                                                  

  Kebudi et al., 2005 \[[@B3]\]                 *N* = 5 \       NR                                   NR                   3--27    Single (3),\                                        None (2);\                  1--6           Literature review included in original study
                                                12--16, M (3)                                                                      multiple (2)                                        RT + chemo (3)                             

                                                                                                                                                                                                                                  

  Yonemoto et al., 2003 \[[@B18]\]              14 F            Right femur                          SR + chemo           26       Tumor infiltration outside the bone cortex          SR + WBRT                   Alive at 72    N/a

                                                                                                                                                                                                                                  

  Paulino et al., 2003 \[[@B17]\]               *N* = 5 \       Femur (2), humerus, tibia, scapula   NR                   10--48   Frontal (3), occipital (1), multiple (1)            SR, chemo, WBRT, None (2)   1--10           
                                                11--19, M (4)                                                                                                                                                                     

                                                                                                                                                                                                                                  

  Weil et al., 2005 \[[@B21]\]                  26 M            Right tibia                          Chemo + SR           36       Skull and brain metastasis                          SR                          4              Patient refused chemo or RT for brain met treatment

                                                                                                                                                                                                                                  

  Bouffet et al., 1997 \[[@B16]\]\              *N* = 3 \       NR                                   NR                   12--15   Supratentorial (2)                                  None\                       2--4            
                                                9-17, M                                                                                                                                RT (2)                                     

                                                                                                                                                                                                                                  

  Wroński et al., 1995 \[[@B5]\]                *N* = 5 \       Femur (3), maxilla humerus           NR                   18--63   Temporal, parietal/occipital (3), posterior fossa   SR                          2.4--13        WBRT was given to select patients (unspecified)
                                                7--26, M (2)                                                                                                                                                                      

                                                                                                                                                                                                                                  

  Chang et al., 1994 \[[@B22]\]                 20 M            Bilateral femur                      (None)               0^a^     Right frontal lobe                                  SR + RT                     5              Early metastasis, multifocal

                                                                                                                                                                                                                                  

  Marina et al., 1993 \[[@B19]\]                3 M             Left humerus                         SR, chemo            4        Temporal and left parietal                          Chemo                       Alive at 108   Additional review of 13 patients

                                                                                                                                                                                                                                  

  Wexler et al., 1993 \[[@B23]\]                10 F            Right femur                          SR, chemo            51       Left parietal and occipital                         SR, WBRT                    Alive at 120   N/a

                                                                                                                                                                                                                                  

  Niedeggen et al., 1990 \[[@B24]\]             7 M             Left femur                           SR, chemo            76       Right parietal lobe                                 SR, RT                      Alive at 13    Histological findings included

                                                                                                                                                                                                                                  

  Baram et al., 1988 \[[@B25]\]                 *N* = 5 \       NR                                   Chemo ± SR           2--46    Frontal (2), multiple (1), NR (2)                   Chemo ± SR                  D              Incidence, clinical, and radiological findings and management
                                                8--15, M (2)                                                                                                                                                                      

                                                                                                                                                                                                                                  

  Lewis, 1988 \[[@B26]\]                        15 F            Right humerus                        Local radiotherapy   0^c^     Left frontal lobe, left corpus callosum             Chemo                       0              Brain lesions discovered upon autopsy

                                                                                                                                                                                                                                  

  Ozarda et al., 1983 \[[@B27]\]                23 M            Right femur                          NR                   8        Right occipital lobe                                Chemo + RT                  NR             Bone scintigraphy usage

                                                                                                                                                                                                                                  

  Danziger et al., 1979 \[[@B28]\]              *N* = 3 \       Right femur (3)                      SR, chemo, RT        6--24    Temporal/occipital, frontoparietal, parietal        Chemo + RT\                 D (2), NR       
                                                18--20, F (3)                                                                                                                          SR, none                                   
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

IB: interval to brain metastasis (mo); OS: overall survival in months; M: male; F: female; chemo: chemotherapy; SR: surgical resection; GKSRS: Gamma knife stereotactic radiosurgery. WBRT: whole brain radiotherapy; RT: radiotherapy; D: death prior to treatment; NR: not reported; ^a^brain metastasis at initial presentation; ^b^alive at last follow-up without recurrence; ^c^brain metastasis at autopsy.

###### 

Comparison of published reports detailing characteristics of patients with brain metastases from Ewing\'s sarcoma.

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Case author                                   Age, sex        Primary site                                         Primary treatment   IB Mo     Metastatic site                                 Metastatic treatment           OS Mo    Special aspects
  --------------------------------------------- --------------- ---------------------------------------------------- ------------------- --------- ----------------------------------------------- ------------------------------ -------- -----------------------------------------------------------------------
  Baid et al., 1992 \[[@B31]\]                  8 M             Left thigh                                           RT\                 1         Right sellar and parasellar region              WBRT                           NR       No response of local disease to chemotherapy
                                                                                                                     chemo                                                                                                                 

  Mineura et al., 1989 \[[@B35]\]               5 F             Axilla                                               SR\                 5         Right occipital region                          SR, WBRT,\                     0        Suppression of blood flow, metabolism of grey matter adjacent to BM
                                                                                                                     chemo                                                                         C, I                                    

  Capitini et al., 2009 \[[@B34]\]              26 M            Left lateral femur                                   RT\                 3         Left parietal and right occipital               SR, WBRT, GKSRS                10       Developed GVHD after allogeneic hematopoietic stem cell transplant
                                                                                                                     chemo                                                                                                                 

  Simpson et al., 1989 \[[@B32]\]               21 M            Right 6th and 7th rib                                SR\                 24        Left parietal cortex                            SR, WBRT                       2^b^     Initial sarcoma misdiagnosed as costochondritis,
                                                                                                                     chemo                                                                                                                 

  Parasuraman et al., 1999 \[[@B36]\]           *N* = 11\       Pelvis (4), humerus, scapula, tibia, vertebrae (2)   RT\                 12--54    Parietal (4), frontal (5), temporal             RT, S, chemotherapy            3        Pediatric case series
                                                5--15, M (5)                                                         chemo                                                                                                                 

  Turgut et al., 1994 \[[@B37]\]                22 M            Sacroiliac joint                                     SR chemotherapy     24        Temporal lobe, parietal                         RT                             8        No active lesion within primary, BM occurred 24 months s/p treatment

  Kies and Kennedy, 1978 \[[@B38]\]             *N* = 3\        NR                                                   RT, chemo           NR        Multiple                                        WBRT                           3        Retrospective analysis of 134 patients with Ewing sarcoma. Found 3 BM
                                                17.4                                                                                                                                                                                       

  Olivi et al., 1991 \[[@B30]\]                 30 F            Rib                                                  SR. RT, chemo       48        Right posterior frontal                         WBRT, S, E, Df\                19^b^    Pancytopenias, and *Pneumocystis carinii* pneumonia.
                                                                                                                                                                                                   C, D                                    

  Chou et al., 2011 \[[@B4]\]                   *N* = 2\        NR                                                   RT, chemo           NR        Multiple                                        Palliative                     NR       Respiratory failure, neuropenian, pneumonia
                                                17--33; M (1)                                                                                                                                                                              

  Salvati et al., 2010, 1998 \[[@B2], [@B9]\]   *N* =5\         Femur (2), sacrum, tibia, ulna                       RT, chemo           1--13     Multiple (2), occipital, frontal, parietal      WBRT/unspecified               NR       Retrospective analysis of 35 cases of supratentorial brain metastases
                                                19--55, M (4)                                                                                                                                                                              

  Paulino et al., 2003 \[[@B17]\]               *N* = 6\        Scapula (2), rib, femur, humerus, pelvis             RT, chemo           0--8      Multiple (2), frontal, parietal, temporal (2)   WBRT + chemo (5), palliative   1.5--9   1 death due to BM
                                                18--20, M                                                                                                                                                                                  

  Ogose et al., 1999 \[[@B33]\]                 *N* = 2\        Thigh, buttock                                       RT, chemo           3-4       Right temporal, occipital                       Conservative                   1--6      
                                                17--44, M (1)                                                                                                                                                                              

  Bindal et al., 1994 \[[@B39]\]                *N* = 4\        Tibia, femur, thigh, chest wall                      NR                  29--115   Multiple (3), frontal                           S (3),WBRT                     NR        
                                                7--58, M (3)                                                                                                                                                                               

  Flannery et al., 2010 \[[@B15]\]              33 F            Pelvis                                               RT, chemo           96        Multiple                                        S,WBRT,GKSRS                   24        

  Bouffet et al., 1997 \[[@B16]\]               17 M            NR                                                   RT, chemo           11        Multiple                                        RT                             2        Patient expired secondary to BM
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

IB: interval to brain metastasis (mo); OS: overall survival in months; M: male; F: female; chemo: chemotherapy; SR: surgical resection; GKSRS: Gamma knife stereotactic radiosurgery. GVHD, graft versus host disease; ICH: intracerebral hemorrhage on presentation; WBRT: whole brain radiotherapy; RT: radiotherapy; D: death; NED: no evidence of disease; NR: not reported; NF: associated with neurofibromatosis type-1; ^a^brain metastasis at initial presentation; ^b^alive at last follow-up without recurrence.

###### 

Comparison of published reports on patients with brain metastases from chondrosarcoma and chordoma.

  Case author                                 Age, sex     IB yr.     BM treatment             OS Mo
  ------------------------------------------- ------------ ---------- ------------------------ ------------
  Chondrosarcoma                                                                               
  Flannery et al., 2010 \[[@B15]\]            14 M, 56 M   0.5--1.3   GKSRS                    18--21
  Francés-Muñoz et al., 2012 \[[@B40]\]       53 F         10         Chemo for lung           NR
  Kawaguchi et al., 2012 \[[@B44]\]           54 M         0.7        Chemo                    52
  Jallu et al., 1992 \[[@B42]\]               54 F         0.7        SR                       NR
  Konishi et al., 1994 \[[@B45]\]             72 F         2          SR                       2
  Reyaz and Ashraf, 2006 \[[@B46]\]           34 F         7          SR                       NR
  Talerman, 1967 \[[@B47]\]                   26 F         ---        ---                      ---
  Templeton et al., 1985 \[[@B48]\]           15 M         34         D                        NR
  Waga et al., 1972 \[[@B49]\]                32 M         12         SR                       NR
  Tsutsumi et al., 2010 \[[@B41]\]            60 M         4.4        Chemo, GKSRS             10+
  Fox et al., 1968 \[[@B50]\]                 51 F         ---        D                        11
                                                                                               
  Chordoma                                                                                     
  Kamel et al., 2005 \[[@B54]\]               12 M         32         SR                       32 (alive)
  Anderson and Meyers, 1968 \[[@B55]\]        69 M         24         SR (gross total)         36 (alive)
  Al-Adra et al., 2011 \[[@B53]\]             29 M         16         SR, WBRT                 ?
  Morris and Rabinovitch, 1947 \[[@B57]\]     41 M         2.5        WBRT                     2.5
  Fichardt and De Villiers, 1974 \[[@B56]\]   59 M         36         SR                       42
  Higinbotham et al. 1967 \[[@B51]\]          58 F         ?          None (autopsy finding)   72
  Mesgarzadeh et al., 2008 \[[@B58]\]         27 F         18         None                     24

Chemo: chemotherapy; D: death prior to treatment; F: female; GKSRS: Gamma knife stereotactic radiosurgery; IB: interval between diagnosis of brain metastasis from chondrosarcoma in years (yr); M: male; NR: not reported; OS: overall survival in months; Radio: radiotherapy; SR: surgical resection; WBRT: whole brain radiotherapy; ^a^diagnosed postmortem; ^b^brain metastasis diagnosed first; +: survival reported for at least the stated amount.

###### 

Comparison of published reports detailing characteristics of patients with brain metastases from fibroblastic and fibrohistiocytic tumors.

  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Case author                                  Age, sex        Tumor type; primary site            Primary treatment   IB Mo      Metastatic site                        Metastatic treatment   OS Mo             Special aspects/\
                                                                                                                                                                                                                  Bone versus soft tissue origin
  -------------------------------------------- --------------- ----------------------------------- ------------------- ---------- -------------------------------------- ---------------------- ----------------- -----------------------------------------------------------------
  Wu et al., 2012 \[[@B60]\]                   32 F            MFH; maxillary sinus                SR (radical); RT    24         Right parietal                         SR; WBRT               25                *Origin: softtissue*

                                                                                                                                                                                                                  

  Graber et al., 2011 \[[@B61]\]               56 M            MFH; aorta                          RT; chemo           0^a^       Multiple                               Biopsy                 ?                 Cystic brain lesion; mimics neurocysticercosis\
                                                                                                                                                                                                                  *Origin: softtissue (aorta)*

                                                                                                                                                                                                                  

  Louis et al., 2007 \[[@B59]\]                38 M            MFH; mandible                       SR; RT              12         Extensive, unspecified^a^              None                   12                MFH associated w/a Marjolin\'s ulcer\
                                                                                                                                                                                                                  *Origin: bone*

                                                                                                                                                                                                                  

  Kousar et al., 2009 \[[@B71]\]               20 F            AFS; mandible                       SR; RT              6          Multiple                               None                   15                *Origin: odontic = bone*

                                                                                                                                                                                                                  

  Hoshi et al., 2008 \[[@B64]\]                45 M            MFH; forearm                        SR; RT; chemo       48         Multiple, parietal, and occipital      Chemo, WBRT            60                Previous lung/bone metastasis at 3 yrs; SC metastasis at 5 yrs\
                                                                                                                                                                                                                  *Origin: softtissue*

                                                                                                                                                                                                                  

  Erguvan-Önal et al., 2004 \[[@B72]\]         45 F            FS; thigh                           SR; RT              2          Right frontal                          SR                     7                 Epitheloid transformation;\
                                                                                                                                                                                                                  *Origin: softtissue*

                                                                                                                                                                                                                  

  Rogers and Whelan, 2000 \[[@B65]\]           *N* = 4\        MFH; humerus, femur, knee, pelvis   Chemo; RT           4--148     Multiple (2), single (2)               RT (2), none (2)       7--153            Previous systemic metastasis in all\
                                               40--54, M (2)                                                                                                                                                      *Origin: bone*

                                                                                                                                                                                                                  

  Ogose et al., 1999 \[[@B33]\]                *N* = 5\        Thigh (3), back                     NR                  0--10      Frontal (3), parietal, temporal        None (2), SR (2)       0.5--16           *Origin: unknown*
                                               40--66, M (2)                                                                                                                                                      

                                                                                                                                                                                                                  

  Salvati et al., 2010 \[[@B2]\]               *N* = 2\        MFH; heart, heart                   RT, chemo           19--21     Frontal                                SR                     9--11             *Origin: soft tissuee*
                                               21--30, M                                                                                                                                                          

                                                                                                                                                                                                                  

  I. A. Auer and R. N. Auer, 1998 \[[@B73]\]   43 M            DFS; abdomen                        NR                  72         Tempro-parietal                        SR                     144               Brain recurrence at 144; prior skin, lung metastasis

                                                                                                                                                                                                                  

  Kim et al., 1997 \[[@B70]\]                  18 F            MFS; heart                          SR, RT, chemo       24         Occipital, cerebellum                  SR, WBRT               50                *Origin: softtissue*

                                                                                                                                                                                                                  

  Jeffery and Ford, 1995 \[[@B68]\]            67 F            FS; abdominal wall                  SR                  60         Right parietal lobe                    None                   61                ICH; previous bone metastasis; *origin: sof-tissue*

                                                                                                                                                                                                                  

  Onoda et al., 1990 \[[@B74]\]                45 M            DFS; upper arm                      SR                  76         Multiple                               none                   84                Lungs, skin

                                                                                                                                                                                                                  

  Wroński et al., 1995 \[[@B5]\]               *N* = 3\        MFH; scalp, thigh, pul.a.           NR                  3--27      Occipital, parietal, posterior fossa   SR                     10.2^b^--65^b^    Lungs
                                               28--67, M (2)                                                                                                                                                      

                                                                                                                                                                                                                  

  Bindal et al., 1994 \[[@B39]\]               *N* = 3\        MFH; trunk, heart, shoulder                             12--2218   Right parietal, multiple (2)           SR, WBRT               2.3^b^--11.8^b^   Prev lungs
                                               25--40, M (2)                                                                                                                                                      

                                                                                                                                                                                                                  

  Lewis, 1988 \[[@B67]\]                       36--53, M       DFS; clavicular; MFH, scapular      SR; RT, chemo       36--312    Multiple                               SR; none^c^            313, LTF          *Origin: softtissue*

                                                                                                                                                                                                                  

  Takamiya et al., 1986 \[[@B66]\]             43 M            FS; pectoralis major                SR                  1          Right frontoparietal                   SR, RT, WBRT           Alive at 13       *Origin: sof-tissue*

                                                                                                                                                                                                                  

  Zucker et al., 1978 \[[@B62]\]               42 F            FS; liver?                          None                24         Pons                                   none                   24                *Origin: softtissue*

                                                                                                                                                                                                                  

  Dal Canto and Valsamis, 1973 \[[@B63]\]      60 F            FS; renal capsule                   None                0          Pons                                   None                   0                 *Origin: softtissue*

                                                                                                                                                                                                                  

  Gercovich et al., 1975 \[[@B43]\]            *N* = 2\        FS; lip, retroperitoneal            Chemo               3--55      Frontal, parietal                      NR                     NR                *Origin: softtissue*
                                               31--52 M                                                                                                                                                           

                                                                                                                                                                                                                  

  Ho, 1979 \[[@B69]\]                          70 F            FS; thigh                           SR (partial)        12         Leptomeninges, cortical                None^c^                NR                *Origin: softtissue*
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

AFS: ameloblastic fibrosarcoma; FS: fibrosarcoma; DFS: dermatofibrosarcoma; IB: interval to brain metastasis (mo); OS: overall survival in months; M: male; F: female; chemo: chemotherapy; GKSRS: Gamma knife stereotactic radiosurgery; MFS: myxofibrosarcoma; ICH: intracerebral hemorrhage on presentation; SR: surgical resection; WBRT: whole brain radiotherapy; RT: radiotherapy; D: death prior to treatment; LTF: lost to follow-up; MFH: malignant fibrous histiocytoma (undifferentiated pleomorphic sarcoma); NR: not reported.

^a^Brain metastasis diagnosed at presentation; ^b^survival after craniotomy; ^c^brain metastasis reported at autopsy.

###### 

Comparison of published reports detailing characteristics of patients with brain metastases from liposarcoma and rhabdomyosarcoma.

  ---------------------------------------------------------------------------------------------------------------------
  Case author                                           Age, sex         IB yr.      BM treatment        OS Mo
  ----------------------------------------------------- ---------------- ----------- ------------------- --------------
  Rhabdomyosarcoma                                                                                       

  Ahola et al., 1998 \[[@B85]\]                         13 M             0.7         SR                  14

  Andersen-Ranberg and Helmer-Hansen, 1987 \[[@B84]\]   19 M             0.5         NR                  6+

  Flannery et al., 2010 \[[@B15]\]                      18 F             5.0         GKSRS, WBRT         60

  Ho, 1979 \[[@B69]\]                                   79 M             ---         D                   ---

  Kebudi et al., 2005 \[[@B3]\]                         11 M             0           RT, Chemo           3

  Kleinert et al., 1985 \[[@B91]\]                      14 F                         D                   48

  Noda et al., 1995 \[[@B92]\]                          2 M              0.5         Chemo, RT           32+

  Ogose et al., 1999 \[[@B33]\]                         7 F, 16 M        NR, 0.2     Chemo, RT           4, 4

  Osawa et al., 2011 \[[@B88]\]                         *N* = 3\         1.1--12.2   SR, RT, Chemo       21--207
                                                        6--18, M (3)                                     

  Paulino et al., 2003 \[[@B17]\]                       *N* = 8\         NR          WBRT, Chemo         2--63
                                                        1.7--18, M (6)                                   

  Rodriguez-Galindo et al., 2001 \[[@B86]\]             *N* = 5\         0.1--1.1    NR                  1.5--24
                                                        Newborn, F                                       

  Salvati et al., 2010 \[[@B2]\]                        *N* = 2\         0.2--0.3    SR                  12.8
                                                        20--22, M (1)                                    

                                                                                                         

  Liposarcoma                                                                                            

  Arepally et al., 1996 \[[@B77]\]                      56 M             312         SR, WBRT            324

  Bailey et al., 2001 \[[@B75]\]                        54 F             108         SR, WBRT            Alive at 114

  Can et al., 1993 \[[@B83]\]                           22 M             0           none                 

  Ferguson et al., 2006 \[[@B80]\]                      48 F             276         RT                  278

  Fitzpatrick et al., 1999 \[[@B78]\]                   74 F             24          SR                  Alive at 30

  Haft et al., 1988 \[[@B81]\]                          52 F             216         SR (total), chemo   228

  Kumar and Teasdale, 2000 \[[@B82]\]                   73 F             12          SR                  Alive at 12

  Salvati et al., 2010 \[[@B2]\]                        48 M             NR          SR                  NR

  Utsunomiya et al., 1999 \[[@B76]\]                    44 M             72          SR (subtotal)       77
  ---------------------------------------------------------------------------------------------------------------------

IB: Interval to brain metastasis (mo); OS: overall survival in months; M: male; F: female; chemo: chemotherapy; SR: surgical resection; GKSRS: Gamma knife stereotactic radiosurgery; ICH: intracerebral hemorrhage on presentation; WBRT: whole brain radiotherapy; RT: radiotherapy; D: death prior to treatment; NR: not reported; UK: unknown; ^a^survival after craniotomy.

###### 

Comparison of published reports detailing characteristics of patients with brain metastases from malignant peripheral nerve sheath tumor (MPNST) and angiosarcoma.

  Case author                                Age, sex   IB yr.   BM treatment          OS Mo
  ------------------------------------------ ---------- -------- --------------------- ----------------
  Malignant peripheral nerve sheath tumors                                             
  Xu et al., 2012 \[[@B94]\]                 8 M        14       (None)                16
  Flannery et al., 2010 \[[@B15]\]           34 F       36       SR, WBRT, GKSRS       48
  Tilgner et al., 2007 \[[@B93]\]            60 M       0^a^     SR, WBRT              Alive at 14
  Park et al., 2007 \[[@B102]\]              21 M       0^a^     SR, WBRT, Chemo       16
  van Eck and Horstmann, 2006 \[[@B101]\]    83 M       108      SR, GKSRS             122
  Matyja et al., 2004 \[[@B95]\]             33 M       \~56     SR                    \~60
  Yone et al., 2004 \[[@B106]\]              4 M        7        WBRT                  21
  Oishi et al., 2000 \[[@B103]\]             48 M       61       SR (en bloc)          NR
  Maschke et al., 1999 \[[@B107]\]           17 F       0^a^     SR                    NR
  Probst-Cousin et al., 1997 \[[@B108]\]     19 F       156      None                  157
  Haisa et al., 1996 \[[@B105]\]             58 F       180      SR (en bloc)          181
  Fenzi et al., 1995 \[[@B100]\]             45 F       5        None                  18
  Seppälä and Haltia, 1993 \[[@B109]\]       13 M       2        None                  2
  D\'Angelo et al., 1991 \[[@B117]\]         68 F       24       SR (en bloc)          36
  Valdueza et al., 1991 \[[@B110]\]          47 M       \~13     None                  18
  Cras et al., 1990 \[[@B111]\]              46 F       0        None                  0
  Hirose et al., 1989 \[[@B112]\]            53 M       15       SR (en bloc), chemo   Alive at 20^b^
  Hasegawa et al., 1984 \[[@B113]\]          51 M       2        Biopsies              3
  Macaulay, 1978 \[[@B114]\]                 18 M       2        None                  2
  White Jr., 1971 \[[@B115]\]                20 M       NR       SR, radiation         7
  D\'Agostino et al., 1963 \[[@B116]\]       22 F       NR       NR                    68
                                                                                       
  Angiosarcoma                                                                         
  Liassides et al., 2004 \[[@B120]\]         24 F       3        Palliative            6
  Eguchi et al., 2002 \[[@B124]\]            64 M       19       Palliative            0
  Chami et al., 1994 \[[@B119]\]             59 M       NR       Palliative            NR
  Vaquero et al., 1990 \[[@B125]\]           30 M       4        SR                    6
  Kuratsu et al., 1991 \[[@B118]\]           17 M       ---      SR                    12
  Haft et al., 1988 \[[@B81]\]               31 F       ---      WBRT                  NR
  Akutsu et al., 2004 \[[@B126]\]            53 M       2        SR                    6
  Ellegala et al., 2002 \[[@B121]\]          76 M       24       SR                    2
  Søndenaa et al., 1993 \[[@B127]\]          73 F       3        Palliative            3
  Gallo et al., 2001 \[[@B129]\]             33 M       12       SR                    0
  Hassane et al., 2010 \[[@B130]\]           48 M       3        Palliative            0
  Simpson et al., 1989 \[[@B32]\]            21 M       24       SR, WBRT              26^b^
  Angrish et al., 1979 \[[@B122]\]           38 M       3        Palliative            0
  Plotnik et al., 2008 \[[@B123]\]           61 F       60       SR                    NR
  Chaudhuri et al., 1980 \[[@B131]\]         31 F       72       SR, WBRT              2
  Macaulay, 1978 \[[@B114]\]                 18 M       2        Palliative            0

IB: interval to brain metastasis (mo); OS: overall survival in months; M: male; F: female; chemo: chemotherapy; SR: surgical resection; GKSRS: Gamma knife stereotactic radiosurgery; ICH: intracerebral hemorrhage on presentation; WBRT: whole brain radiotherapy; RT: radiotherapy; D: death prior to treatment; NR: not reported; NF: associated with neurofibromatosis type-1; ^a^brain metastasis at initial presentation.; ^b^alive at last follow-up without recurrence.

###### 

Summary of cases of alveolar soft part sarcoma with brain metastases as reported in previous published series.

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Case Author                         *N*   Age, sex             Primary site                                                                        Primary treatment   IB Mo                *N* with BM   Metastatic treatment\*   OS\* (Mo)                                                                                              Special aspects
  ----------------------------------- ----- -------------------- ----------------------------------------------------------------------------------- ------------------- -------------------- ------------- ------------------------ ------------------------------------------------------------------------------------------------------ ----------------------------------------------------------------------------------------------------
  Daigeler et al., 2008 \[[@B132]\]   11    19--24, M (7)        Thigh (2), lower leg (2), thoracic wall (2), upper arm (2), forearm (1), Foot (1)   SR; chemo with RT   78 months (5--156)   3/11\         SR, RT                   73% of patients are still alive at follow-up with no evidence of disease                               Localized disease, complete resection. And adjuvant radiation within 2 years had favorable outcome

                                                                                                                                                                                                                                                                                                                                            

  Kayton et al., 2006 \[[@B141]\]     20    16.5; 6--24,\        Thigh (8), trunk (6), Retroperito. (2), scalp, neck, forearm, calf                  SR, chemo, RT       36 months            2/20          SR                       Follow-up: patients were alive after mean 22 years (4--32 years)                                       Tumors, 5 cm were associated with longer progression-free survival
                                            M (10)                                                                                                                                                                                                                                                                                          

                                                                                                                                                                                                                                                                                                                                            

  Park et al., 1999 \[[@B142]\]       6     24.5 (17--35)\       Femur (3), fibula (2), ilium                                                        SR, chemo, RT       10--12 months        2/6           N/A                      Follow-up range of patients with no evidence of disease (7 mo.--8 yrs.)                                ASPS arising in bone
                                            (2) M                                                                                                                                                                                                                                                                                           

                                                                                                                                                                                                                                                                                                                                            

  Portera et al., 2001 \[[@B137]\]    74    26 (3--68)\          Extremities (60%), trunk (20%), head and neck (12%), Retroper. (8%)                 SR; RT; chemo       5--24 months         14/74         Chemo                    Median was 41 months for patients w/o metastasis and 40 months with metastasis                          
                                            49% male                                                                                                                                                                                                                                                                                        

                                                                                                                                                                                                                                                                                                                                            

  Bindal et al., 1994 \[[@B39]\]      2     40--48\              Thigh, rectum                                                                       SR                  1--15 months         2/2           SR                       Still alive after 24.7 and 16.4 months                                                                  
                                            1 male                                                                                                                                                                                                                                                                                          

                                                                                                                                                                                                                                                                                                                                            

  Flannery et al., 2010 \[[@B15]\]    2     42.4 (14--74)        Leg, gluteal                                                                        Chemo and SR        30--48 months        2/2           SR                       Survived from 5 to 7 years after surgery with no evidence of disease; 31--36 months after metastasis    

                                                                                                                                                                                                                                                                                                                                            

  Salvati et al., 2010 \[[@B2]\]      3     35 (19--61); males   Thigh (100%)                                                                        SR                  24--58 months        3/3                                    Alive from 15 to 24 months after SR with no evidence of disease                                         

                                                                                                                                                                                                                                                                                                                                            

  Wroński et al., 1995 \[[@B5]\]      2     7--14\               Thigh, tongue                                                                       SR                  23 months            2/2           SR                       Alive 2.7--23 months SR with no evidence of disease                                                     
                                            1 male                                                                                                                                                                                                                                                                                          

                                                                                                                                                                                                                                                                                                                                            

  Chou et al., 2011 \[[@B4]\]         4     25 (17--33); M       NR                                                                                  SR and RT           14.53 months         4/4           SR and RT                3 dead; 1 still alive                                                                                   
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

\*Some results are reported for an entire series of ASPS patients, and not necessarily only those with BM; ASPS: alveolar soft part sarcoma; BM: brain metastasis; IB: interval to brain metastasis (mo); OS: overall survival in months; M: male; F: female; chemo: chemotherapy; SR: surgical resection; GKSRS: Gamma knife stereotactic radiosurgery; ICH: intracerebral hemorrhage on presentation; WBRT: whole brain radiotherapy; RT: radiotherapy; D: death prior to treatment; NR: not reported; UK: unknown; ^a^survival after craniotomy.

[^1]: Academic Editor: Shreyaskumar Patel
